Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy

International Journal of Cancer

Volumn 54, Issue 2, 1993, Pages 177-180

  Boon, Thierry ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTIGENS, NEOPLASM; HUMAN; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0027252779     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910540202     Document Type: Article

References (30)

1. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide
2. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens
3. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line
4. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line
5. Human gene MAGE‐1, which codes for a tumor rejection antigen, is expressed by some breast tumors
6. Construction and applications of a highly transmissible murine retrovirus shuttle vector
7. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells
8. Tum‐ variants of mouse mastocytoma P815. IX. Cloning of the gene of tum ‐ antigen P91A and identification of the tum‐ mutation
9. Interleukin‐2 production by tumor cells bypasses T helper function in the generation of an antitumor response
10. Antigenic properties of methylcholanthrene‐induced tumors in mice of the strain of origin
11. Treatment of established renal cancer by tumor cells engineered to secrete interleukin‐4
12. Human T lymphocytes recognize a peptide of single point‐mutated, oncogenic ras proteins
13. Protection against lethal Sendai virus infection by in vivo priming of virus‐specific cytotoxic T lymphocytes with a free synthetic peptide
14. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas
15. Structure of the gene coding for tum‐ transplantation antigen P91A. A peptide encoded by the mutated exon is recognized with Ld by cytolytic T cells
16. T cell recognition of transforming proteins encoded by mutated ras proto‐oncogenes
17. Immunity to methylcholanthrene‐induced sarcomas
18. Induction of antigen‐specific class I‐restricted cytotoxic T cells by soluble proteins in vivo
19. Structure of the gene of tum‐ transplantation antigen P198: a point mutation generates a new antigenic peptide
20. New use of BCG for recombinant vaccines
21. Structure of the gene of tum‐ transplantation antigen P35B: presence of a point mutation in the antigenic allele
22. Non‐replicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
23. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides
24. A nonapeptide encoded by human gene MAGE‐1 is recognized on HLA‐A1 by CTL directed against tumor antigen MZ2‐E
25. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes
26. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice
27. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
28. Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus‐induced tumors. III. Characterization of cytolytic T lymphocyte clones specificity for Moloney leukemia
29. Cytolytic response of human T cells against allogeneic small cell lung carcinoma treated with interferon gamma
30. Galactose oxidation in the design of immunogenic vaccines